News
SANA
3.070
-2.54%
-0.080
Sana Biotechnology (SANA) Gets a Buy from Morgan Stanley
TipRanks · 05/18 12:57
Weekly Report: what happened at SANA last week (0511-0515)?
Weekly Report · 05/18 09:23
Sana Biotechnology Raises $69 Million Through Equity Offering
TipRanks · 05/15 20:50
Sana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market Facility
Dow Jones · 05/15 13:31
Sana Biotechnology raises $69M through ATM share sale
Seeking Alpha · 05/15 13:26
Sana Biotechnology Announces Aggregate Sales Of 21,607,878 Shares With Net Proceeds Of ~$69M Through Its ATM Facility Established With TD Securities
Benzinga · 05/15 13:03
Sana Biotechnology sells 21,607,878 shares via ATM for net proceeds of $69 million
PUBT · 05/15 13:02
SANA BIOTECHNOLOGY ANNOUNCES SALE OF APPROXIMATELY $69 MILLION OF SHARES THROUGH ITS AT-THE-MARKET (ATM) FACILITY
Reuters · 05/15 13:00
Sana Biotechnology (SANA) Receives a Buy from Wedbush
TipRanks · 05/13 14:18
Sana Biotechnology presents preclinical data for in vivo CAR T cell therapy
TipRanks · 05/12 22:28
Sana Biotechnology Presents Preclinical Data Showing Surrogate SG293 Achieves Cell-Specific Delivery, Dose-Dependent CAR T Cell Generation, And Deep B Cell Depletion In NHPs At ASGCT 2026 Annual Meeting
Benzinga · 05/12 20:20
Sana plans SG293 in vivo CAR-T trial in non-Hodgkin lymphoma later 2026
PUBT · 05/12 20:09
Bank of America Securities Keeps Their Buy Rating on Sana Biotechnology (SANA)
TipRanks · 05/12 10:56
Sana Biotechnologies: Mayo Collaboration and HIP Platform Progress Reinforce Buy Rating and Unchanged $7 Price Target
TipRanks · 05/12 10:16
Frahm Initiates Buy on Sana Biotechnology, Citing Differentiated In Vivo CAR‑T Pipeline and Strong Cash Runway into 2027
TipRanks · 05/12 00:05
Sana Biotechnology reports Q1 non-GAAP EPS (14c), consensus (15c)
TipRanks · 05/11 20:42
Sana Biotechnology Q1 Adj. EPS $(0.14) Beats $(0.17) Estimate
Benzinga · 05/11 20:25
Sana Biotechnology GAAP EPS of -$0.17 in-line
Seeking Alpha · 05/11 20:21
Sana Biotechnology posts Q1 adjusted loss narrower than expected, extends cash runway
Reuters · 05/11 20:19
Sana Biotechnology Q1 FY26 net loss narrows to $47.2 million
PUBT · 05/11 20:11
More
Webull provides a variety of real-time SANA stock news. You can receive the latest news about Sana Biotechnology, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SANA
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), oncology, and B cell mediated autoimmune diseases. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline products include SC451 and UP421. SC451 is its HIP-edited product candidate for the treatment of type 1 diabetes. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. Its ex vivo cell engineering platform is focused on engineering hypoimmune cells that engraft, function, and persist in patients by evading immune rejection.